Summary A range of new anthracyclines, structurally related to adriamycin (ADM), has been synthesised and studied in vitro. Three compounds described in this paper (Ro 31-1215; Ro 31-1741; Ro 31-2035) are all 4-demethoxyanthracyclines. In the mouse mammary tumour cell line, EMT6/Ca/VJAC, using a 1 h drug exposure followed by colony formation as the response endpoint, we found Ro 31-1215 and Ro 31-1741 to be 2-3 x and 4-7 x more potent then ADM, whilst Ro 31-2035 was 3-4 x less potent. For continuous drug exposure and suppression of population growth as the endpoint, the potency of Ro 31-1741 was similar to that of ADM, whereas that of Ro 31-1215 was 1.5-2 x higher and that of Ro al., 1978; Kaye & Merry, 1985) . The mechanism of such resistance is currently the subject of much ongoing laboratory work and a variety of strategies for overcoming resistance are being investigated (Tsuruo et al., 1983; Skovsgaard et al., 1984) .
The anthracycline antibiotic adriamycin (doxorubicin, ADM) is one of the most useful clinical cytotoxic drugs. It is used for the treatment of a wide range of malignant diseases ranging from the leukaemias to solid tumours such as lung and ovarian carcinomas (Davis & Davis 1979 ). The major dose-limiting toxicity of ADM is cardiomyopathy which appears to be dependent upon the total accumulated drug dose (Minow et al., 1975) . There is also a variety of evidence which suggests that clinical effectiveness of ADM may be limited by the development of cellular resistance to the drug (Hubbard et al., 1978; Kaye & Merry, 1985) . The mechanism of such resistance is currently the subject of much ongoing laboratory work and a variety of strategies for overcoming resistance are being investigated (Tsuruo et al., 1983; Skovsgaard et al., 1984) .
Over the last 10 years a large number of analogues of ADM have been produced with the major objective of finding a drug which is less cardiotoxic for a given amount of anti-tumour effect (Naff et al., 1982) . To Figure 1 . ADM, Ro 31-1215 and Ro 31-1741 were dissolved in distilled water at 500 pgml-1 and aliquots stored at -20°C. Ro 31-2035 was dissolved in propylene glycol at 500 pg ml-1 and aliquots stored at -20°C. Drugs days a number of small areas of cell growth were observed and these were allowed to develop with medium change where necessary for 4 weeks. At this time the cells were transferred to a new flask and the concentration of ADM increased to 1.0pgml-1. After a further 4 weeks of passage in 1.0ygml-1 the variant line EMT6(AR) was defined and a frozen stock established in liquid nitrogen using medium containing 10% DMSO. A similar method was used to obtain a variant line EMT6(1215R) by alternate growth in the presence or absence of Ro 31-1215 at final concentration of 0.1 Igml-1. The human small cell lung cancer line NCI-H69 was originally supplied to us by Dr D. Carney of the NCI/Navy Medical Oncology Branch. This line grows as floating aggregates of cells in RPMI 1640 medium supplemented with 10% foetal calf serum (Gibco Biocult). We have produced ADM resistant variants of this line by a complicated regime of growth in the presence and absence of ADM (Twentyman et al., 1985) and these are designated 'H69/LX' (maintained in 0.1 jIg ml -1 ADM) and 'H69/LX4' (maintained in 0.4pgml-l ADM). The parent line is designated 'H69/P'.
Two other human lung cancer cell lines, COR-L47 (small cell) and COR-L23 (large cell) were used in a limited number of experiments. The former grows as floating aggregates and the latter as an attached monolayer in RMPI 1640 + 10% foetal calf serum (Baillie-Johnson et al., 1985) .
Response experiments Experiments to measure the drug response of EMT6 cells (and resistant variants) were carried out in one of three different ways.
(a) Acute I h exposure with clonogenic assay Cells were inocultated into a number of 25 cm2 culture flasks (Falcon) at 105 cells/flask and allowed to grow for 2 days. During this period, ADM or Ro 31-1215 resistant variants were grown in the absence of drug. Cultures were then treated for 1 h by addition of the test drug to the growth medium and, at the end of this time, rinsed twice and a single cell suspension obtained using trypsin (0.075%) for 15min at 37°C. Cells were counted using a haemocytometer, dilutions made, and appropriate numbers of cells inoculated into 9cm diameter plastic petri dishes (Sterlin) in 10ml of medium. The dishes were incubated at 37°C in 8% CO2 +92% air for 10 days at which time the dishes were rinsed, fixed and stained with crystal violet. Colonies containing more than 50 cells were then enumerated. The plating efficiency of EMT6 was in excess of 80% whilst that of EMT6(AR) was in the range 30-50%. Drug uptake The content of ADM or Ro 31-1215 in NCI-H69 (P and LX4) grown in the continuous presence of the drug was determined using our previously described (Twentyman et al., 1985) adaptation of the method of Schwartz (1973) . Cells were grown for 24 or 48 h in the drugs and after rinsing they were lysed, treated with silver nitrate and the drug extracted using isoamyl alcohol. Fluorescence was measured using a Perkin-Elmer MPF4 spectrofluorimeter with an excitation wavelength of 490 nm and an emission wavelength of 560 nm (Ro 31-1215) or 595 nm (ADM).
Determination ofpartition coefficients
Partition coefficients were obtained by measuring the fluorescence of drug solutions in Dulbecco 'A' PBS, pH 7.4, before and after prolonged extraction with n-octanol at 4°C. Duplicate 4ml samples of a solution of each drug (5ug ml-1 in PBS) were extracted with an equal volume of octanol overnight, in the dark, on a rotating wheel. Duplicate control solutions were not extracted. After centrifugation the octanol layer was removed and the fluorescence (F) of the aqueous layer determined as described above for ADM and Ro 31-1215. For Ro 31-1741 and Ro 31-2035, excitation wavelengths of 485 and 470 nm respectively and an emission wavelength of 565 nm were used. The partition coefficient was given by:
In view of the pH used and the potential for ionisation, the values obtained are, strictly speaking, apparent partition coefficients or distribution coefficients.
Results
Response of EMT6 and EMT6(AR) cells -acute (I h) exposure Survival data for EMT6 mouse tumour cells exposed for 1 h to the various anthracyclines (assay method (a)) are shown in Figure 2 . From data such as these, a value of ID80 (acute) is obtained as the drug dose at which the best line fitted by eye to the data crosses a surviving fraction of 0.2 (i.e. 80% inhibition of colony growth). In almost all cases, Experiments similar to those shown in Figure 3 and using total cells per dish after 3 days as the endpoint (i.e. assay method (c)) were carried out to determine the response of EMT6 and EMT6 (Figure 6 and Table IV) . In 4 experiments, however, the resistance factor of H69/LX4 cells to 
Discussion
The three novel anthracyclines described in this paper are members of a larger group of compounds recently produced by total synthesis. They are all 4-demethoxyanthracyclines. The particular interest in 4-demethoxy compounds is based on the analysis by Naff et al. (1982) of NCI screening data of over 400 anthracyclines. The overall activity of daunomycin analogues was found to increase as the 4-position substitutent was changed from OCH3 to OH to H and, in the ADM series, the activity of 4-demethoxyadriamycin was greater than that of ADM. The three compounds which we have studied were selected from a large group on the basis of preliminary in vivo screening data carried out in a mouse L1210 model system and a mouse mammary tumour (Hartmann et al., 1985) . The compound Ro 31-2035 is also believed to be considerably less cardiotoxic than ADM (Hartmann, personal communication) . Our data indicate that the relative potencies of the agents in our in vitro tesing systems depend upon the method of testing. Although in all cases, Ro 31-2035 was found to be less potent than ADM, the factor was 3 x for a 1 h exposure of EMT6 cells and 6-20 x for various experiments using continuous exposure of either EMT6 or NCI-H69 cells. Similarly, whereas Ro 31-1215 and Ro 31-1741 were 2-4 x and 4-7 x respectively more potent than ADM for 1 h exposure in EMT6, the factors for continuous exposure indicate that Ro 31-1215 is a little less potent than ADM whilst Ro 31-1741 is 1-2 x more potent. These differences may be due to the widely different lipophilicities of the different compounds. A comparison of the cellular pharmacokinetics of ADM (partition coefficient, PC= 0.5) and aclacinomycin A (PC = 21.8) (Zenebergh et al., 1982) (Robert et al., 1982) . The relative contributions of these various phases to overall tumour response is not established, although there appeared to be a correlation between tumour response and a parameter related to the early phase of plasma clearance (Robert et al., 1982) . Recent in vitro concentration x time studies using NCI-H69 cells (Twentyman & Fox, in preparation) (Giavazzi et al., 1983) and similar conclusions were reached by Schabel et al. (1983) using an ADM-resistant subline of P388 leukaemia. For aclacinomycin A (ACL), however, little loss of activity appears to occur in ADM-resistant lines (Tsuruo et al., 1983; Hill et al., 1985; Twentyman et al., 1985) . In addition, retention of activity in an ADM-resistant line of L51 78Y lymphoma was seen for 4 anthracyclines (including 4'deoxyadriamycin) by Hill et al. (1985) . However, the ADM-resistance factor for this line was low. Our own studies for 4'deoxyadriamycin (Twentyman et al., 1985) show as great a loss of activity as that seen for ADM.
The data presented in this paper for Ro 31-1215 indicate that it is of similar efficiency to ACL in overcoming ADM-resistance (Twentyman et al., 1985) . The subline H69/LX of small cell lung cancer line NCI-H69, is resistant to ADM by a factor which varies between 4 and 30 in individual experiments, but is not resistant to either ACL or Ro 31-1215. The subline H69/LX4 (resistance factor for ADM=40-200) is resistant to ACL and Ro 31-1215 by 2-4 x . We therefore believe that Ro 31-1215 is as good a candidate as ACL for an anthracycline with retained activity in ADMresistant cells. Our studies on cellular content of ADM and Ro 31-1215 during prolonged incubation indicate that cellular pharmacokinetic differences may be involved in these relative resistance characteristics. It is interesting that EMT6 cells made resistant to Ro 31-1215 by growth in the drug show a higher resistance factor for ADM than they do for Ro 31-1215 itself. This may indicate that the mechanism of resistance in these cells is the same as that in cells made resistant by growth in ADM. Additional studies using compounds synthesised by Roche Products (Scott et al., 1985; have determined that several 9-methyl and 9-ethyl substituted 4-demethoxy anthracyclines also show retention of activity in ADM-resistant cells. This may indicate the prime importance of a 9-alkyl substitution in conferring such a property. The fact that ACL also has a 9-alkyl group would support this proposition.
We are currently carying out detailed studies in animal systems designed to compare directly the 3 novel anthracyclines reported in this paper with ADM in terms of therapeutic efficiency. Studies into the relative cardiotoxicity of the compounds are also in progress.
